At a glance
ClinicalIndex Comparison Record- ✓Stage IV or locally advanced unresectable gastrointestinal adenocarcinoma (gastric, GEJ, cholangiocarcinoma, hepatocellular, pancreatic, colorectal, small intestinal) that has failed at least one prior therapy
- ✓For pancreatic adenocarcinoma: histologic diagnosis with locally advanced unresectable or metastatic disease failed at least one standard regimen
- ✓For colorectal adenocarcinoma: histologic diagnosis with locally advanced unresectable or metastatic disease; prior exposure to oxaliplatin, irinotecan, and fluoropyrimidine required
- ✓Measurable disease per RECIST 1.1
- ✕Prior anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy
- ✕Prior anti-cancer monoclonal antibody within 4 weeks before study day 1 or inadequate recovery from prior agents administered >4 weeks earlier
- ✕Prior chemotherapy, targeted therapy, or radiation within 2 weeks of study day 1 or inadequate recovery; ≤grade 2 neuropathy allowed as exception
- ✕Clinically significant cardiovascular disease (MI, unstable angina within 6 months), symptomatic CHF, serious uncontrolled arrhythmia, QTc >450 msec, or prior QT prolongation with other medications
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase Ib Trial of Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Malignancies
In Brief
A Phase 1 clinical trial evaluating XL888 and Pembrolizumab for Colorectal Adenocarcinoma and 14 related conditions. Completed, enrolled 47 participants across 3 sites.
Detailed Summary
This phase Ib trial studies the side effects and best dose of Hsp90 inhibitor XL888 when given together with pembrolizumab in treating patients with advanced gastrointestinal cancer that has spread to other places in the body. XL888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving XL888 with pembrolizumab may work better in treating patients with gastrointestinal cancer.
Study Details
Timeline
Interventions
Given PO
Given IV